Drug Profile

FL 115

Alternative Names: FL-115

Latest Information Update: 19 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Suzhou Forlong Biotechnology
Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
Mechanism of Action Interleukin 15 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Bladder cancer; Solid tumours

Most Recent Events

08 Jan 2026 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy, Second-line therapy or greater) in China (IV) (NCT07131202)
07 Jan 2026 The NMPA accepts the IND application for FL 115 subcutaneous injection
30 Oct 2025 Efficacy and adverse event data from a phase I/II trial in Bladder cancer released by Suzhou Forlong Biotechnology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com